HBsAg Seroclearance: Prognostic value for the response to treatment and the long-term outcome;Négativation de l'antigène HBs: valeur pronostique pour la réponse au traitement et l'évolution à long terme

Gastroenterologie Clinique et Biologique

Volumn 34, Issue SUPPL. 2, 2010, Pages

  Moucari, R ^a   Marcellin, P ^a  

^a BEAUJON HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CIRCULAR DNA; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; INTERFERON; NUCLEOSIDE ANALOG; NUCLEOTIDE DERIVATIVE; PEGINTERFERON;

ARTICLE; CHRONIC HEPATITIS; HEPATITIS B; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; PATIENT MONITORING; PROGNOSIS; SURVIVAL TIME; TREATMENT OUTCOME;

ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; DNA, VIRAL; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; PROGNOSIS;

EID: 78649365376     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0399-8320(10)70031-2     Document Type: Article

References (65)

1. Liaw Y.F., Chu C.M. Hepatitis B virus infection. Lancet 2009, 373:582-592.
2. Hsu Y.S., Chien R.N., Yeh C.T., Sheen I.S., Chiou H.Y., Chu C.M., et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatol 2002, 35:1522-1527.
3. Chu C.M., Hung S.J., Lin J., Tai D.I., Liaw Y.F. Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase levels. Am J Med 2004, 116:829-834.
4. Liaw Y.F., Sheen I.S., Chen T.J., Chu C.M., Pao C.C. Incidence, determinants and significance of delayed clearance of serum HBsAg in chronic hepatitis B virus infection: a prospective study. Hepatol 1991, 13:627-631.
5. Chu C.M., Liaw Y.F. Natural history differences in perinatally versus adult-acquired disease. Curr Hepat Rep 2004, 3:123-131.
6. Chu C.M., Liaw Y.F. HBsAg seroclearance in asymptomatic carriers of high endemic areas: appreciably high rates during a long-term follow-up. Hepatol 2007, 45:1187-1192.
7. Sampliner R.E., Hamilton F.A., Iseri O.A., Tabor E., Boitnott J. The liver histology and frequency of clearance of the hepatitis B surface antigen (HBsAg) in chronic carriers. Am J Med Sci 1979, 277:17-22.
8. Alward W.L., McMahon B.J., Hall D.B., Heyward W.L., Francis D.P., Bender T.R. The long-term serological course of asymptomatic hepatitis B virus carriers and the development of primary hepatocellular carcinoma. J Infect Dis 1985, 151:604-609.
9. Furusyo N., Hayashi J., Sawayama Y., Kishihara Y., Kashiwagi S. Hepatitis B surface antigen disappearance and hepatitis B surface antigen subtype: a prospective, long-term, follow-up study of Japanese residents of Okinawa, Japan with chronic hepatitis B virus infection. Am J Trop Med Hyg 1999, 60:616-622.
10. Kato Y., Nakao K., Hamasaki K., Kato H., Nakata K., Kusumoto Y., et al. Spontaneous loss of hepatitis B surface antigen in chronic carriers, based on a long-term follow-up study in Goto Islands, Japan. J Gastroenterol 2000, 35:201-205.
11. Villeneuve J.P., Desrochers M., Infante-Rivard C., Willems B., Raymond G., Bourcier M., et al. A long-term follow-up study of asymptomatic hepatitis B surface antigen-positive carriers in Montreal. Gastroenterol 1994, 106:1000-1005.
12. McMahon B.J., Holck P., Bulkow L., Snowball M. Serologic and clinical outcomes of 1536 Alaska Natives chronically infected with hepatitis B virus. Ann Intern Med 2001, 135:759-768.
13. Manno M., Cammà C., Schepis F., Bassi F., Gelmini R., Giannini F., et al. Natural history of chronic HBV carriers in northern Italy: morbidity and mortality after 30 years. Gastroenterol 2004, 127:756-763.
14. Wu T.T., Hsu H.C., Chen D.S., Sheu J.C., Su I.J., Chen S.L., et al. Clearance of hepatitis B surface antigen (HBsAg) after surgical resection of hepatocellular carcinoma. J Hepatol 1987, 4:45-51.
15. Kim J.H., Lee J.H., Park S.J., Bae M.H., Kim J.H., Kim do Y., et al. Factors associated with natural seroclearance of hepatitis B surface antigen and prognosis after seroclearance: a prospective follow-up study. Hepatogastroenterol 2008, 55:578-581.
16. Da Silva L.C., Madruga C.L., Carrilho F.J., Pinho J.R., Saéz-Alquezar A., Santos C., et al. Spontaneous hepatitis B surface antigen clearance in a long-term follow-up study of patients with chronic type B hepatitis. Lack of correlation with hepatitis C and D virus superinfection. J Gastroenterol 1996, 31:696-701.
17. Sánchez-Tapias J.M., Costa J., Mas A., Bruguera M., Rodés J. Influence of hepatitis B virus genotype on the long-term outcome of chronic hepatitis B in western patients. Gastroenterol 2002, 123:1848-1856.
18. Fattovich G., Giustina G., Sanchez-Tapias J., Quero C., Mas A., Olivotto P.G., et al. Delayed clearance of serum HBsAg in compensated cirrhosis B: relation to interferon alpha therapy and disease prognosis. European Concerted Action on Viral Hepatitis (EUROHEP). Am J Gastroenterol 1998, 93:896-900.
19. Chen Y.C., Chu C.M., Yeh C.T., Liaw Y.F. Natural course following the onset of cirrhosis in patients with chronic hepatitis B: a long-term follow-up study. Hepatol Intl 2007, 1:267-273.
20. Korenman J., Baker B., Waggoner J., Everhart J.E., Di Bisceglie A.M., Hoofnagle J.H. Long-term remission of chronic hepatitis B after alpha-interferon therapy. Ann Intern Med 1991, 114:629-634.
21. Lau D.T., Everhart J., Kleiner D.E., et al. Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa. Gastroenterol 1997, 113:1660-1667.
22. Teuber G., Dienes H.P., Meyer Zum Büschenfelde K.H., Gerken G. Long-term follow-up of patients with chronic hepatitis B after interferon treatment. Z Gastroenterol 1996, 34:230-236.
23. Niederau C., Heintges T., Lange S., Goldmann G., Niederau C.M., Mohr L., et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996, 334:1422-1427.
24. van Zonneveld M., Honkoop P., Hansen B.E., Niesters H.G., Darwish Murad S., de Man R.A., et al. Long-term follow-up of alphainterferon treatment of patients with chronic hepatitis B. Hepatol 2004, 39:804-810.
25. Buster E.H., Flink H.J., Cakaloglu Y., Simon K., Trojan J., Tabak F., et al. Sustained HBeAg and HBsAg loss after long-term follow- up of HBeAg-positive patients treated with peginterferon alpha-2b. Gastroenterol 2008, 135:459-467.
26. Moucari R., Korevaar A., Lada O., Martinot-Peignoux M., Boyer N., Mackiewicz V., et al. High rates of HBsAg seroconversion in HBeAgpositive chronic hepatitis B patients responding to interferon: a long-term follow-up study. J Hepatol 2009, 50:1084-1092.
27. Marcellin P., Bonino F., Lau G.K., Farci P., Yurdaydin C., Piratvisuth T., et al. Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a. Gastroenterol 2009, 136:2169-2179.
28. Lampertico P., Del Ninno E., Viganò M., Romeo R., Donato M.F., Sablon E., et al. Long-term suppression of hepatitis B e antigennegative chronic hepatitis B by 24-month interferon therapy. Hepatol 2003, 37:756-763.
29. Lok A.S., Chung H.T., Liu V.W., Ma O.C. Long-term follow-up of chronic hepatitis B patients treated with interferon alfa. Gastroenterol 1993, 105:1833-1838.
30. Yuen M.F., Hui C.K., Cheng C.C., Wu C.H., Lai Y.P., Lai C.L. Long-term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: The effect on hepatitis B e antigen seroconversion and the development of cirrhosisrelated complications. Hepatol 2001, 34:139-145.
31. Lin S.M., Yu M.L., Lee C.M., Chien R.N., Sheen I.S., Chu C.M., et al. Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. J Hepatol 2007, 46:45-52.
32. Carreño V., Castillo I., Molina J., Porres J.C., Bartolomé J. Longterm follow-up of hepatitis B chronic carriers who responded to interferon therapy. J Hepatol 1992, 15:102-106.
33. Fattovich G., Giustina G., Realdi G., Corrocher R., Schalm S.W. Long-term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alfa. European Concerted Action on Viral Hepatitis (EUROHEP). Hepatol 1997, 26:1338-1342.
34. Krogsgaard K. Executive Team on Anti-Viral Treatment. J Viral Hepat 1998, 5:389-397. The long-term effect of treatment with interferon-alpha 2a in chronic hepatitis B. The Long-Term Follow-up Investigator Group. The European Study Group on Viral Hepatitis (EUROHEP).
35. Mazzella G., Saracco G., Festi D., Rosina F., Marchetto S., Jaboli F., et al. Long-term results with interferon therapy in chronic type B hepatitis: a prospective randomized trial. Am J Gastroenterol 1999, 94:2246-2250.
36. Papatheodoridis G.V., Manesis E., Hadziyannis S.J. The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B. J Hepatol 2001, 34:306-313.
37. Moucari R., Martinot-Peignoux M., Mackiewicz V., Boyer N., Ripault M.P., Castelnau C., et al. Influence of genotype on hepatitis B surface antigen kinetics in hepatitis B e antigen-negative patients treated with pegylated interferon-alpha2a. Antivir Ther 2009, 14:1183-1188.
38. Marcellin P., Heathcote E.J., Buti M., Gane E., de Man R.A., Krastev Z., et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008, 359:2442-2455.
39. Heathcote E.J., Gane E., deMan R.A., Chan S., Sievert W., Mauss S., et al. Two year tenofovir disoproxil fumarate (TDF) treatment and adefovir dipivoxil (ADV) switch data in HBeAg-positive patients with chronic hepatitis B (study 103), preliminary analysis. Hepatol 2008, 48:376A.
40. Marcellin P., Chang T.T., Lim S.G., Sievert W., Tong M., Arterburn S., et al. Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Hepatol 2008, 48:750-758.
41. Hadziyannis S.J., Tassopoulos N.C., Heathcote E.J., Chang T.T., Kitis G., Rizzetto M., et al. Long-term therapy with adefovir dipivoxil for HBeAg negative chronic hepatitis B for up to 5 years. Gastroenterol 2006, 131:1743-1751.
42. Han S.H.B., Chang T.T., Chao Y.C., Yoon S.K., Gish R.G., Cheinquer H., et al. Five years of continuous entecavir for nucleoside-naïve HBeAg (+) chronic hepatitis B: results from study ETV-901. Hepatol 2008, 48:705A.
43. Werle-Lapostolle B., Bowden S., Locarnini S., Wursthorn K., Petersen J., Lau G., et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterol 2004, 126:1750-1758.
44. Wong D.K., Yuen M.F., Ngai V.W., Fung J., Lai C.L. One-year entecavir or lamivudine therapy results in reduction of hepatitis B virus intrahepatic covalently closed circular DNA levels. Antivir Ther 2006, 11:909-916.
45. Wursthorn K., Lutgehetmann M., Dandri M., Volz T., Buggisch P., Zollner B., et al. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatol 2006, 44:675-684.
46. Chan H.L., Wong V.W., Tse A.M., Tse C.H., Chim A.M., Chan H.Y., et al. Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response. Clin Gastroenterol Hepatol 2007, 5:1462-1468.
47. Ahn S.H., Park Y.N., Park J.Y., Chang H.Y., Lee J.M., Shin J.E., et al. Long-term clinical and histological outcomes in patients with spontaneous hepatitis B surface antigen seroclearance. J Hepatol 2005, 42:188-194.
48. Arase Y., Ikeda K., Suzuki F., Suzuki Y., Saitoh S., Kobayashi M., et al. Long-term outcome after hepatitis B surface antigen seroclearance in patients with chronic hepatitis B. Am J Med 2006, 119:71.e9-71.e16.
49. Yuen M.F., Wong D.K., Fung J., Ip P., But D., Hung I., et al. HBsAg Seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma. Gastroenterol 2008, 135:1192-1199.
50. Loriot M.A., Marcellin P., Walker F., Boyer N., Degott C., Randrianatoavina I., et al. Persistence of hepatitis B virus DNA in serum and liver from patients with chronic hepatitis B after loss of HBsAg. J Hepatol 1997, 27:251-258.
51. Arase Y., Suzuki F., Suzuki Y., Saitoh S., Kobayashi M., Akuta N., et al. Long-term presence of HBV in the sera of chronic hepatitis B patients with HBsAg seroclearance. Intervirol 2007, 50:161-165.
52. Lau G.K., Hepatitis B reactivation after chemotherapy: two decades of clinical research. Hepatol Int 2008, 2:152-162.
53. Chen Y.C., Sheen I.S., Chu C.M., Liaw Y.F. Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection. Gastroenterol 2002, 123:1084-1089.
54. Chu C.M., Liaw Y.F. HBsAg seroclearance in Asian patients: too high and too bad in Hong Kong. Gastroenterol 2009, 136:1459-1460.
55. Chung H.T., Lai C.L., Lok A.S. Pathogenic role of hepatitis B virus in hepatitis B surface antigen-negative decompensated cirrhosis. Hepatol 1995, 22:25-29.
56. Tong M.J., Nguyen M.O., Tong L.T., Blatt L.M. Development of hepatocellular carcinoma after seroclearance of hepatitis B surface antigen. Clin Gastroenterol Hepatol 2009, 7:889-893.
57. Volz T., Lutgehetmann M., Wachtler P., Jacob A., Quaas A., Murray J.M., et al. Impaired intrahepatic hepatitis B virus productivity contributes to low viremia in most HBeAg-negative patients. Gastroenterol 2007, 133:843-852.
58. Manesis E.K., Hadziyannis E.S., Angelopoulou O.P., Hadziyannis S.J. Prediction of treatment-related HBsAg loss in HBeAg-negative chronic hepatitis B: a clue from serum HBsAg levels. Antivir Ther 2007, 12:73-82.
59. Fattovich G., Olivari N., Pasino M., D'Onofrio M., Martone E., Donato F. Long-term outcome of chronic hepatitis B in Caucasian patients: mortality after 25 years. Gut 2008, 57:84-90.
60. Moucari R., Lada O., Marcellin P. Chronic hepatitis B: back to the future with HBsAg. Expert Rev Anti Infect Ther 2009, 7:633-636.
61. Janssen H.L., Kerhof-Los C.J., Heijtink R.A., Schalm S.W. Measurement of HBsAg to monitor hepatitis B viral replication in patients on alpha-interferon therapy. Antiviral Res 1994, 23:251-257.
62. Moucari R, Boyer N, Ripault MP, Castelnau C, Mackiewicz V, Dauvergne A, et al. Sequential therapy with adefovir dipivoxil and pegylated interferon alfa-2a for HBeAg-negative patients. J Viral Hepat 2010; in press.
63. Moucari R., Mackiewicz V., Lada O., Ripault M.P., Castelnau C., Martinot-Peignoux M., et al. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatol 2009, 49:1151-1157.
64. Brunetto M.R., Moriconi F., Bonino F., Lau G.K., Farci P., Yurdaydin C., et al. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatol 2009, 49:1141-1150.
65. Moucari R., Bourlière M., Ripault M.P., Castelnau C., Mackiewicz V., Dauvergne A., et al. HBsAg decline in chronic hepatitis B patients treated with potent NUCs. Hepatol 2009, 50:507A.